Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BO 112

Next Previous
Search
Drug Profile

BO 112

Alternative Names: BO-112; Nanoplexed Poly IC BO-112; Nanoplexed Polyinosinic:Polycytidylic Acid BO-112

Latest Information Update: 11 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bioncotech Therapeutics
  • Developer Highlight Therapeutics; Merck Sharp & Dohme; UCLAs Jonsson Comprehensive Cancer Center
  • Class Antineoplastics; Immunotherapies; RNA
  • Mechanism of Action DDX58 protein stimulants; IFIH1 interferon-induced helicase stimulants; Immunostimulants; PMAIP1 protein stimulants; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Basal cell cancer; Colorectal cancer; Gastric cancer; Malignant melanoma
  • Phase I/II Non-small cell lung cancer
  • No development reported Liver cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 29 Nov 2024 Highight Therapeutics terminates a phase II trial in Gastric cancer and Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, Italy and Belgium (Intratumoural) due to low recruitment rate (NCT04508140) (EudraCT2019-004624-38)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Liver-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intratumoural, Injection)
  • 27 May 2024 Phase-II clinical trials in Basal cell cancer in Israel (Intralesional) (NCT06422936)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top